Summary
REGN has been providing a lot of news on important products lately.
It announced earnings Tuesday, which were solid, but Eylea growth has slowed.
In this update on REGN, I'm focusing on tying the existing products and some of its potential long-term growth drivers into one picture of the company.
REGN may not have visibility for alpha for the year ahead, but the reasons why I have a certain allocation to it with a very long-term time frame may interest some readers.
It's a Buffett-type approach for a very non-Buffett-style stock, and risks are significant.
Introduction
Regeneron's (REGN) Q3 earnings report and conference call join with some recent news to make this an update of why I continue to hold this as one of a tiny number of non-dividend paying stocks in this retiree's portfolio. Based on many promising marketed and pipeline opportunities, I am looking at REGN as a true multi-year investment, Warren Buffett-style. In that sort of time frame, basically with a 5-10-year perspective, current Fed policy and the latest economic (or election) news drop out. What I see is that REGN is the only mid-sized US biotech that has numerous attributes which are in the good or great range (all subjectively judged by yours truly, not scientific in any way), including:
